Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medifast (MED) Operating Expenses (2016 - 2025)

Medifast's Operating Expenses history spans 16 years, with the latest figure at $59.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 31.5% year-over-year to $59.9 million; the TTM value through Dec 2025 reached $289.4 million, down 34.49%, while the annual FY2025 figure was $289.4 million, 34.49% down from the prior year.
  • Operating Expenses reached $59.9 million in Q4 2025 per MED's latest filing, down from $66.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $272.7 million in Q2 2022 to a low of $59.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $162.4 million, with a median of $161.9 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 77.04% in 2021, then tumbled 40.82% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $231.4 million in 2021, then decreased by 13.16% to $201.0 million in 2022, then plummeted by 33.98% to $132.7 million in 2023, then crashed by 34.05% to $87.5 million in 2024, then crashed by 31.5% to $59.9 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Operating Expenses are $59.9 million (Q4 2025), $66.2 million (Q3 2025), and $77.7 million (Q2 2025).